Vera Therapeutics (NASDAQ:VERA) CEO Marshall Fordyce Sells 18,500 Shares of Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $37.93, for a total value of $701,705.00. Following the completion of the sale, the chief executive officer owned 198,244 shares in the company, valued at approximately $7,519,394.92. This trade represents a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce also recently made the following trade(s):

• On Tuesday, May 12th, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The stock was sold at an average price of $36.74, for a total value of $679,690.00.
• On Tuesday, April 14th, Marshall Fordyce sold 22,951 shares of Vera Therapeutics stock. The stock was sold at an average price of $44.05, for a total value of $1,010,991.55.

Vera Therapeutics Price Performance

Vera Therapeutics stock traded up $1.31 during midday trading on Wednesday, reaching $39.51. The company’s stock had a trading volume of 2,473,781 shares, compared to its average volume of 1,164,046. Vera Therapeutics, Inc. has a fifty-two week low of $19.07 and a fifty-two week high of $56.05. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. The stock’s 50 day simple moving average is $36.24 and its 200 day simple moving average is $41.53. The firm has a market capitalization of $2.84 billion, a PE ratio of -7.13 and a beta of 0.93.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the prior year, the firm posted ($0.81) EPS. On average, equities research analysts forecast that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current year.

Institutional Trading of Vera Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its stake in shares of Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after acquiring an additional 236 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in Vera Therapeutics in the 4th quarter valued at about $46,000. Aster Capital Management DIFC Ltd acquired a new position in Vera Therapeutics in the 4th quarter valued at about $71,000. Quantbot Technologies LP purchased a new position in Vera Therapeutics in the 2nd quarter valued at about $51,000. Finally, Sandia Investment Management LP acquired a new stake in shares of Vera Therapeutics during the 4th quarter worth about $127,000. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. HC Wainwright raised their price objective on Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Evercore set a $91.00 price target on Vera Therapeutics in a research report on Friday, May 15th. Finally, Wolfe Research raised Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target for the company in a research note on Wednesday, March 11th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Vera Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $78.00.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.